Sept. 20, 2005 (Atlanta) — Results from the STAR trial, comparing two new-generation antimuscarinics solifenacin and tolterodine extended release (ER), suggest that solifenacin is superior in reducing ...

Astellas Pharma announced results from the Phase 3b BESIDE trial of solifenacin (SOLI) with mirabegron (MIRA) as an add-on therapy in incontinent overactive bladder (OAB) patients. The BESIDE study is ...

Antimuscarinics have remained the standard of care for patients with overactive bladder (OAB) syndrome for several decades, despite the fact that, owing to their adverse effects, these drugs are ...

The US Food and Drug Administration (FDA) has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate (Vesicare, Astellas Pharma) for the treatment of overactive ...

Do not use if you have ever had an allergic reaction to SOLIFENACIN VIATRIS or any of the ingredients listed at the end of the CMI. There are a number of circumstances in which a person should not use ...

Solifenacin (Bispec (10 mg)) is a urinary antispasmodic agent, prescribed for overactive bladder with or without incontinence.It works by blocking the action of certain chemicals in the body to help ...

Discover the commercial and brand names of the generic drug Solifenacin . This indispensable guide is essential for healthcare professionals, patients, caregivers, and anyone seeking to understand the ...

In clinical trials, the combination of Myrbetriq + solifenacin succinate was associated with greater improvements in the number of incontinence episodes per 24 hours (primary endpoint), the number of ...

NEW DELHI: Strides Pharma Science Friday said its step-down wholly-owned subsidiary has received approval from the US health regulator for Solifenacin Succinate tablets, used to treat overactive ...